Format

Send to

Choose Destination
EBioMedicine. 2019 Feb;40:554-563. doi: 10.1016/j.ebiom.2018.12.052. Epub 2019 Jan 5.

Senolytics in idiopathic pulmonary fibrosis: Results from a first-in-human, open-label, pilot study.

Author information

1
Sticht Center for Healthy Aging and Alzheimer's Prevention, Internal Medicine - Gerontology and Geriatric Medicine, Wake Forest School of Medicine (WFSM), 1 Medical Center Blvd, Winston-Salem, NC 27157, United States. Electronic address: jnjustic@wakehealth.edu.
2
Division of Pulmonary Diseases and Critical Care Medicine, Department of Internal Medicine, University of Texas Health Sciences Center at San Antonio (UTHSCSA) and South Texas Veterans Health Care System, San Antonio, TX 78229, United States. Electronic address: Nambiar@uthscsa.edu.
3
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Tchkonia.Tamar@mayo.edu.
4
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: LeBrasseur.Nathan@mayo.edu.
5
Internal Medicine - Pulmonary, Critical Care, Allergy, Immunologic Medicine, Wake Forest School of Medicine, 1 Medical Center Blvd, Winston-Salem, NC 27157, United States. Electronic address: rpascual@wakehealth.edu.
6
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Hashmi.Shahrukh@mayo.edu.
7
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: prata.larissa@mayo.edu.
8
Burnett School of Biomedical Sciences, University of Central Florida, Orlando, FL 32827, United States. Electronic address: michal.masternak@ucf.edu.
9
Sticht Center for Healthy Aging and Alzheimer's Prevention, Internal Medicine - Gerontology and Geriatric Medicine, Wake Forest School of Medicine (WFSM), 1 Medical Center Blvd, Winston-Salem, NC 27157, United States. Electronic address: skritche@wakehealth.edu.
10
Barshop Institute for Longevity and Aging Studies, Center for Healthy Aging, University of Texas Health Sciences Center at San Antonio and South Texas Veterans Health Care System, San Antonio, TX 78229, United States; San Antonio Geriatric Research, Education and Clinical Center, South Texas Veterans Health Care System, San Antonio, TX 78229, United States. Electronic address: Musi@uthscsa.edu.
11
Robert and Arlene Kogod Center on Aging, Mayo Clinic, Rochester, MN 55905, United States. Electronic address: Kirkland.James@mayo.edu.

Abstract

BACKGROUND:

Cellular senescence is a key mechanism that drives age-related diseases, but has yet to be targeted therapeutically in humans. Idiopathic pulmonary fibrosis (IPF) is a progressive, fatal cellular senescence-associated disease. Selectively ablating senescent cells using dasatinib plus quercetin (DQ) alleviates IPF-related dysfunction in bleomycin-administered mice.

METHODS:

A two-center, open-label study of intermittent DQ (D:100 mg/day, Q:1250 mg/day, three-days/week over three-weeks) was conducted in participants with IPF (n = 14) to evaluate feasibility of implementing a senolytic intervention. The primary endpoints were retention rates and completion rates for planned clinical assessments. Secondary endpoints were safety and change in functional and reported health measures. Associations with the senescence-associated secretory phenotype (SASP) were explored.

FINDINGS:

Fourteen patients with stable IPF were recruited. The retention rate was 100% with no DQ discontinuation; planned clinical assessments were complete in 13/14 participants. One serious adverse event was reported. Non-serious events were primarily mild-moderate, with respiratory symptoms (n = 16 total events), skin irritation/bruising (n = 14), and gastrointestinal discomfort (n = 12) being most frequent. Physical function evaluated as 6-min walk distance, 4-m gait speed, and chair-stands time was significantly and clinically-meaningfully improved (p < .05). Pulmonary function, clinical chemistries, frailty index (FI-LAB), and reported health were unchanged. DQ effects on circulat.ing SASP factors were inconclusive, but correlations were observed between change in function and change in SASP-related matrix-remodeling proteins, microRNAs, and pro-inflammatory cytokines (23/48 markers r ≥ 0.50).

INTERPRETATION:

Our first-in-humans open-label pilot supports study feasibility and provides initial evidence that senolytics may alleviate physical dysfunction in IPF, warranting evaluation of DQ in larger randomized controlled trials for senescence-related diseases. ClinicalTrials.gov identifier: NCT02874989 (posted 2016-2018).

KEYWORDS:

Aging; Cellular senescence; Clinical trial; Idiopathic pulmonary fibrosis; Interstitial lung disease; Senolytics; Translation

Supplemental Content

Full text links

Icon for Elsevier Science Icon for PubMed Central
Loading ...
Support Center